The authors regret that a footnote was missing in Table I. The footnote is for Intestine D under the Others heading. The corrected table appears below.
Table I.
Patient́s Characteristics, Status Before and Response to DC Vaccination
. | . | . | . | Metastases at study entry . | . | . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | . | Regional . | . | Distant . | . | . | . | . | . | . | ||||||||||||
| Patientcode . | Sexage . | Center . | Previoustherapy . | Skin . | LN . | Skin . | LN . | Lung . | Liver . | Skeleton . | Others . | Clinicalresponse . | ||||||||||||
| Fully evaluable patients (five vaccinations) | ||||||||||||||||||||||||
| 02 | m-48 | E | S, ILP, IT, RT, CIT | - | - | - | - | D/5 | - | - | Pancreas 2/35 | CR | ||||||||||||
| 05 | f-77 | E | S, ILP, IT, RT, CT | 6/34 | - | - | - | - | - | - | SD | |||||||||||||
| 08 | f-64 | E | S, IT, CIT, CT | - | - | 1/3 | 1/4 | - | 2/80 | - | Muscle 1/60 | OP | ||||||||||||
| 10 | m-41 | E | S, IT | - | 2/13 | - | - | - | - | - | SD | |||||||||||||
| 12 | f-65 | E | S, CT | - | - | - | 1/15 | D/10 | - | - | SD | |||||||||||||
| 14 | m-58 | E | S, IT, CT | - | - | - | - | D/25 | - | - | OP | |||||||||||||
| 15 | f-35 | E | S, CIT | - | 2/20 | - | - | - | - | - | SD | |||||||||||||
| 16 | m-63 | I | S | - | 2/30 | - | 1/25 | - | - | 1/20 | OP | |||||||||||||
| 17 | f-60 | I | S, CIT | - | - | D/10 | 3/26 | 1/3 | - | Kidney 2/15, suprarenal 2/60 | OP | |||||||||||||
| 18 | m-77 | I | S | - | - | - | - | 3/30 | 1/14 | 3/60 | OP | |||||||||||||
| 19 | m-70 | E | S, IT | - | - | - | - | 9/25 | - | 2/25 | OP | |||||||||||||
| 20 | m-64 | E | S, IT, RT | D (>50)/5 | - | D/5 | - | - | - | - | SD | |||||||||||||
| 21 | m-59 | E | S, IT | - | 2/9 | - | - | - | - | - | SD | |||||||||||||
| 23 | f-36 | E | S, IT, CT | 3/14 | - | - | - | - | - | - | Intestine Da | SD | ||||||||||||
| 27 | f-44 | I | S, IT | - | - | - | 1/51 | 1/16 | - | - | SD | |||||||||||||
| 28 | m-55 | E | S, CIT, ILP | - | 2/6 | - | 3/30 | - | - | - | OP | |||||||||||||
| Not fully evaluable patients (less than five vaccinations) | ||||||||||||||||||||||||
| 01 | f-29 | E | CIT | - | - | - | D/8 | - | 1/5 | - | Spleen 3/35 peritoneum D muscle 2/30 | † | ||||||||||||
| 03 | m-59 | E | S, IT, CT | 1/70 | D/15 | - | - | - | - | - | Sinus cavernosus infiltration; bone | † | ||||||||||||
| 04 | f-55 | E | S, IT, CT | - | - | D/30 | - | - | - | OP | ||||||||||||||
| 07 | f-48 | I | S, CIT, RT | - | 1/20 | - | D/50 | - | - | - | OP | |||||||||||||
| 09 | m-57 | E | S, CIT | 1/11 | - | - | D | - | D | - | Pancreas, duodenum, gastric D | OP | ||||||||||||
| 11 | f-71 | E | S | D (>50)/5 | - | - | - | - | - | OP | ||||||||||||||
| 13 | f-49 | I | S | - | - | - | D/35 | - | - | - | OP | |||||||||||||
| 24 | f-37 | I | S, CT, IT, RT | - | - | - | 1/45 | 1/20 | - | - | OP | |||||||||||||
. | . | . | . | Metastases at study entry . | . | . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | . | Regional . | . | Distant . | . | . | . | . | . | . | ||||||||||||
| Patientcode . | Sexage . | Center . | Previoustherapy . | Skin . | LN . | Skin . | LN . | Lung . | Liver . | Skeleton . | Others . | Clinicalresponse . | ||||||||||||
| Fully evaluable patients (five vaccinations) | ||||||||||||||||||||||||
| 02 | m-48 | E | S, ILP, IT, RT, CIT | - | - | - | - | D/5 | - | - | Pancreas 2/35 | CR | ||||||||||||
| 05 | f-77 | E | S, ILP, IT, RT, CT | 6/34 | - | - | - | - | - | - | SD | |||||||||||||
| 08 | f-64 | E | S, IT, CIT, CT | - | - | 1/3 | 1/4 | - | 2/80 | - | Muscle 1/60 | OP | ||||||||||||
| 10 | m-41 | E | S, IT | - | 2/13 | - | - | - | - | - | SD | |||||||||||||
| 12 | f-65 | E | S, CT | - | - | - | 1/15 | D/10 | - | - | SD | |||||||||||||
| 14 | m-58 | E | S, IT, CT | - | - | - | - | D/25 | - | - | OP | |||||||||||||
| 15 | f-35 | E | S, CIT | - | 2/20 | - | - | - | - | - | SD | |||||||||||||
| 16 | m-63 | I | S | - | 2/30 | - | 1/25 | - | - | 1/20 | OP | |||||||||||||
| 17 | f-60 | I | S, CIT | - | - | D/10 | 3/26 | 1/3 | - | Kidney 2/15, suprarenal 2/60 | OP | |||||||||||||
| 18 | m-77 | I | S | - | - | - | - | 3/30 | 1/14 | 3/60 | OP | |||||||||||||
| 19 | m-70 | E | S, IT | - | - | - | - | 9/25 | - | 2/25 | OP | |||||||||||||
| 20 | m-64 | E | S, IT, RT | D (>50)/5 | - | D/5 | - | - | - | - | SD | |||||||||||||
| 21 | m-59 | E | S, IT | - | 2/9 | - | - | - | - | - | SD | |||||||||||||
| 23 | f-36 | E | S, IT, CT | 3/14 | - | - | - | - | - | - | Intestine Da | SD | ||||||||||||
| 27 | f-44 | I | S, IT | - | - | - | 1/51 | 1/16 | - | - | SD | |||||||||||||
| 28 | m-55 | E | S, CIT, ILP | - | 2/6 | - | 3/30 | - | - | - | OP | |||||||||||||
| Not fully evaluable patients (less than five vaccinations) | ||||||||||||||||||||||||
| 01 | f-29 | E | CIT | - | - | - | D/8 | - | 1/5 | - | Spleen 3/35 peritoneum D muscle 2/30 | † | ||||||||||||
| 03 | m-59 | E | S, IT, CT | 1/70 | D/15 | - | - | - | - | - | Sinus cavernosus infiltration; bone | † | ||||||||||||
| 04 | f-55 | E | S, IT, CT | - | - | D/30 | - | - | - | OP | ||||||||||||||
| 07 | f-48 | I | S, CIT, RT | - | 1/20 | - | D/50 | - | - | - | OP | |||||||||||||
| 09 | m-57 | E | S, CIT | 1/11 | - | - | D | - | D | - | Pancreas, duodenum, gastric D | OP | ||||||||||||
| 11 | f-71 | E | S | D (>50)/5 | - | - | - | - | - | OP | ||||||||||||||
| 13 | f-49 | I | S | - | - | - | D/35 | - | - | - | OP | |||||||||||||
| 24 | f-37 | I | S, CT, IT, RT | - | - | - | 1/45 | 1/20 | - | - | OP | |||||||||||||
†
Deceased.
a
Surgically removed prior to therapy.
Treatment Centers: E, Erlangen; I, Innsbruck.
Pretreatment therapy: IT, immunotherapy; C(I)T, chemo(immuno)therapy; S, surgery.
RT, radiotherapy; ILP, isolated limb perfusion.
Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in mm); D, diffuse.
Clinical Response: CR, complete regression; OP, overall progression; SD, stable disease.
The Rockefeller University Press
2003
